1. American Cancer Society. Breast Cancer Facts & Figures 2009-2010, 2009.
2. Poortmans PM, Collette L, Bartelink H, et al. for the EORTC Radiation Oncology and Breast Cancer Groups. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. Cancer Radiother. 12(6-7):565-570, 2008.
3. Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer. 113(9):2565-74, 2008.
4. Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 100(16):1179-83, 2008.
5. Auvinen A, Curtis RE and Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst. 94: 1330-2, 2002.
6. Hemminki K, Scelo G, Boffetta P, et al. Second primary malignancies in patients with male breast cancer. Br J Cancer. 92: 1288-92, 2005.
7. Raymond JS, Hogue CJR. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer. 94(11):1745-50, 2006.
8. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 62: 676-89, 1998.
9. Schrag D, Kuntz KM, Garber JE and Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 283: 617-24, 2000.
10. Isaacs C, Peshkin BN, Schwartz M. Chapter 19: Evaluation and management of women with a strong family history, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott Williams and Wilkins, 2004.
11. Andersson M, Jensen MB, Engholm G, Storm HH. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001.Acta Oncol. 47(4):755-64, 200
12. National Health and Medical Research Council. Clinical practice guidelines for the management of early breast cancer, 2nd edition, 2001.
13. American Cancer Society. Detailed guide: Male breast cancer. What happens after treatment for breast cancer in men? 2008. http://www.cancer.org/.
14. National Comprehensive Cancer Network (NCCN). NCCN Practice Guidelines in Oncology: Breast cancer screening and diagnosis guidelines, version 1.2008, 2008.
15. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 21: 4042-57, 2003.
16. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 345: 1719-26, 2001.
17. Michael YL, Berkman LF, Colditz GA, et al. Social networks and health-related quality of life in breast cancer survivors: a prospective study. J Psychosom Res. 52: 285-93, 2002.
18. Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol. 21(21):4027-33, 2003.
19. Rowland JH, Massie MJ. Chapter 90: Issues in breast cancer survivorship, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott Williams and Wilkins, 2004.
20. Pieterse K, van Dooren S, Seynaeve C, et al. Passive coping and psychological distress in women adhering to regular breast cancer surveillance. Psychooncology. 16(9):851-8, 2007.
21. Waxler-Morrison N, Hislop TG, Mears B, et al. Effects of social relationships on survival for women with breast cancer: a prospective study. Soc Sci Med. 33(2):177-183, 1991.
22. Reynolds P, Boyd PT, Blacklow RS, et al. The relationship between social ties and survival among black and white breast cancer patients. National Cancer Institute Black/White Cancer Survival Study Group. Cancer Epidemiol Biomarkers Prev. 3: 253-9, 1994.
23. Weihs KL, Simmens SJ, Mizrahi J, Enright TM, Hunt ME, Siegel RS. Dependable social relationships predict overall survival in Stages II and III breast carcinoma patients. J Psychosom Res. 59(5):299-306, 2005.
24. Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol. 24(7):1105-11, 2006.
25. Bordeleau L, Szalai JP, Ennis M, et al. Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data. J Clin Oncol. 21(10):1944-51, 2003.
26. Edwards AGK, Hulbert-Williams N, Neal RD. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev. (3):CD004253, 2008.
27. Phillips KA, Osborne RH, Giles GG, et al. Psychosocial factors and survival of young women with breast cancer: a population-based prospective cohort study. J Clin Oncol. 26(28):4666-71, 2008.
28. Herman DR, Ganz PA, Petersen L, Greendale GA. Obesity and cardiovascular risk factors in younger breast cancer survivors: The Cancer and Menopause Study (CAMS). Breast Cancer Res Treat. 93(1):13-23, 2005.
29. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 175(1):34-41, 2006.
30. Kirshbaum MN. A review of the benefits of whole body exercise during and after treatment for breast cancer. J Clin Nurs. 16(1):104-21, 2007.
31. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 23(7):1370-8, 2005.
32. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 14(8):2009-14, 2005.
33. Tao MH, Shu XO, Ruan ZX, Gao YT, Zheng W. Association of overweight with breast cancer survival. Am J Epidemiol. 163(2):101-7, 2006.
34. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. s obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 111(2):329-42, 2008.
35. McTiernan A, Rajan KB, Tworoger SS, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 21(10):1961-6, 2003.
36. Irwin ML, McTiernan A, Bernstein L, et al. Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 14(12):2881-8, 2005.
37. Holmes MD, Stampfer MJ, Colditz GA, et al. Dietary factors and the survival of women with breast carcinoma. Cancer. 86(5):826-35, 1999.
38. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 98(24):1767-76, 2006.
39. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA. 298(3):289-98, 2007.
40. Kushi LH, Byers T, Doyle C. for the American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 56(6):323-53, 2006.
41. Siteman Cancer Center at Washington University School of Medicine. Your Disease Risk. http://www.yourdiseaserisk.wustl.edu, 2009.
42. National Cancer Institute. Lymphedema: Overview. www.cancer.gov, 2008.
43. Petrek JA and Chevile AL. Chapter 91: Lymphedema, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott Williams and Wilkins, 2004.
44. Meeske KA, Sullivan-Halley J, Smith AW, et al. Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. Breast Cancer Res Treat. 2008 Feb 24. [Epub ahead of print].
45. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 98(9):599-609, 2006.
46. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 13(4):491-500, 2006.
47. McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 26(32):5213-9, 2008.
48. McNeely ML, Magee DJ, Lees AW, Bagnell KM, Haykowsky M, Hanson J. The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat. 86(2):95-106, 2004.
49. Koul R, Dufan T, Russell C, et al. Efficacy of complete decongestive therapy and manual lymphatic drainage on treatment-related lymphedema in breast cancer. Int J Radiat Oncol Biol Phys. 67(3):841-6, 2007.
50. Hamner JB, Fleming MD. Lymphedema therapy reduces the volume of edema and pain in patients with breast cancer. Ann Surg Oncol. 14(6):1904-8, 2007.
51. Vignes S, Porcher R, Arrault M, Dupuy A. Long-term management of breast cancer-related lymphedema after intensive decongestive physiotherapy. Breast Cancer Res Treat. 101(3):285-90, 2007.
52. Sander AP, Hajer NM, Hemenway K, Miller AC. Upper-extremity volume measurements in women with lymphedema: a comparison of measurements obtained via water displacement with geometrically determined volume. Phys Ther. 82(12):1201-12, 2002.
53. Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat. 89(3):221-6, 2005.
54. Deltombe T, Jamart J, Recloux S, et al. Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema. Lymphology. 40(1):26-34, 2007.
55. Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer.112(12):2809-19, 2008.
56. Hayes S, Cornish B, Newman B. Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 26(21):3536-42, 2008.
57. Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 16: 501-14, 1998.
58. Beckjord E, Campas BE. Sexual quality of life in women with newly diagnosed breast cancer. J Psychosoc Oncol. 25(2):19-36, 2007.
59. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol. 26(5):753-8, 2008.
60. Fobair P, Stewart SL, Chang S, D'Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology. 15(7):579-94, 2006.
61. .Mueller BA, Simon MS, Deapen D, et al. Childbearing and survival after breast carcinoma in young women. Cancer. 98(6): 1131-40, 2003.
62. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B. Pregnancy after treatment of breast cancer--a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol. 47(4):545-9, 2008.
63. Higgins S and Haffty BG. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer. 73: 2175-80, 1994.
64. Moran MS, Colasanto JM, Haffty BG, Wilson LD, Lund MW, Higgins SA. Effects of breast-conserving therapy on lactation after pregnancy. Cancer J. 11(5):399-403, 2005.
65. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 350: 1047-59, 1997.
66. Rossouw JE, Anderson GL, Prentice RL, et al. for the Women's Health Initiative (WHI) Investigators Writing Group. Risk and benefits of estrogen plus progestin in health postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 288(3):321-33, 2002.
67. Anderson GL, Limacher M, Assaf AR, et al. for The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial. JAMA. 291(14):1701-12, 2004.
68. Holmberg L, Iverson OE, Rudenstam CM, et al., for the HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.J Natl Cancer Inst. 100(7):475-82, 2008.
69. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute. Facts about menopause hormone therapy. NIH publication no. 05-5200, http://www.nhlbi.gov/health/women/pht_facts.htm, 2005.
70. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 356: 2059-63, 2000.
71. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 20(6):1578-83, 2002.
72. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 23(28):6919-30, 2005.
73. Kimmick GG, Lovato J, McQuellon R, Robinson E, Hyman B. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 12(2):114-22, 2006.
74. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist. 12(1):124-35, 2007.
75. Buijs C, Mom CH, Willemse PHB, et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat. 2008 Aug 1. [Epub ahead of print]
76. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 366(9488):818-24, 2005.
77. Loprinzi CL, Kugler JW, Barton DL, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 25(3):308-12, 2007.
78. Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 82: 1784-8, 1998.
79. Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 26(10):1650-6, 2008.
80. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 16: 495-500, 1998.
81. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 18(5): 1068-74, 2000.
82. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 20(6):1449-55, 2002.
83. Nahas EAP, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira MLCS, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas. 58(3):249-58, 2007.
84. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 24(18):2836-41, 2006.
85. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. 145(12):869-79, 2006
86. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause. 15(1):51-8, 2008.
87. National Institutes of Health. NIH State-of-the-Science Conference Statement on Management of Menopause-Related Symptoms. http://consensus.nih.gov/2005/2005MenopausalSymptomsSOS025html.htm, 2005.
88. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 11(1):11-33, 2004.
89. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 355(22):2338-47, 2006.
90. Boekhout AH, Beijnen JH, Schellens JHM. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist.11(6):641-54, 2006.
91. Lewis JE, Nickell LA, Thompson LU, Szalai JP, Kiss A, Hilditch JR. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause. 13(4):631-42, 2006.
92. Dorsey CM, Lee KA, Scharf MB. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 26(10):1578-86, 2004.
93. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol. 19(10):1669-80, 2008.
94. Claus EB, Schildkraut J, Iversen ES, Jr., et al. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst. 90: 1824-9, 1998.
95. Couto E and Hemminki K. Estimates of heritable and environmental components of familial breast cancer using family history information. Br J Cancer. 96(11):1740-2, 2007.
Updated 10/19/09
